The long shadow cast by COVID-19 is moving deeper into the territory of cardiovascular medicine. A randomized, double-blind, placebo-controlled trial published in Nature Communications examines whether two established drugs—losartan and prednisolone—can influence post-COVID syndrome and signs of cardiac inflammation. The study, led by Victor O. Puntmann, Eike Nagel and colleagues, addresses a question that has remained difficult to resolve since the earliest waves of the pandemic: can persistent symptoms after SARS-CoV-2 infection be treated by targeting biological processes that continue after the virus itself is no longer detectable?
Post-COVID syndrome, often called long COVID, describes a broad collection of symptoms that persist or emerge after the acute infection has passed. Patients may experience exhaustion, shortness of breath, rapid or irregular heartbeats, chest discomfort, impaired concentration and reduced exercise capacity. The condition is biologically diverse, and researchers have implicated several overlapping mechanisms, including immune dysregulation, damage to the vascular lining, abnormal clotting, autonomic nervous-system disturbances and persistent inflammation. In some patients, imaging and laboratory studies also suggest that the heart can remain affected even when conventional tests appear normal.
The trial focuses on cardiac inflammation, a process in which immune activity can damage or disrupt heart muscle and the tissues surrounding it. Inflammation may interfere with the contraction of cardiomyocytes, alter the electrical properties of the heart and impair the function of small blood vessels that supply cardiac tissue. Magnetic resonance imaging can detect patterns such as myocardial edema, fibrosis or abnormal tissue enhancement, while blood tests may identify cellular stress or injury. These measurements are important because symptoms alone cannot reliably distinguish inflammatory heart disease from deconditioning, lung damage, anxiety or other consequences of viral infection.
Losartan belongs to a class of medicines known as angiotensin-receptor blockers. It inhibits the action of angiotensin II, a hormone that constricts blood vessels and contributes to blood pressure regulation. Excessive or prolonged activation of the renin–angiotensin system has also been associated with vascular dysfunction, oxidative stress, fibrosis and inflammatory signaling. By blocking the angiotensin II type 1 receptor, losartan can reduce some of these effects. The drug is already widely used for hypertension and certain forms of cardiovascular and kidney disease, making its safety profile better established than that of many experimental treatments.
Prednisolone takes a different pharmacological route. It is a synthetic glucocorticoid that enters cells and changes gene transcription, broadly suppressing the production and activity of inflammatory mediators. Corticosteroids can reduce immune-cell activation, tissue swelling and cytokine signaling, but their wide-ranging effects also mean that treatment must be carefully balanced. Potential concerns include elevated blood glucose, susceptibility to infection, mood changes, fluid retention and other complications, particularly when treatment is prolonged or given to people with underlying health risks.
Testing the two medicines in a controlled clinical trial is crucial because biological plausibility does not guarantee clinical benefit. A drug may improve a laboratory marker without improving fatigue, exercise tolerance or quality of life, or it may help one subgroup of patients while offering little value to another. The randomized design helps distribute known and unknown factors between treatment groups. Participants are assigned by chance, reducing the likelihood that differences in age, illness severity, previous medical conditions or time since infection will distort the comparison.
The double-blind structure adds another layer of protection against bias. Neither participants nor the investigators assessing them know who receives active treatment and who receives placebo during the blinded phase. This matters particularly in post-COVID research, where symptoms can fluctuate and expectations about treatment may influence how patients report their health. Placebo comparison also allows researchers to separate a genuine pharmacological effect from the natural recovery that occurs in some people, as well as from the benefits of medical attention and structured follow-up.
The trial’s importance extends beyond these two medications. SARS-CoV-2 can affect the cardiovascular system through direct injury, immune-mediated damage, endothelial dysfunction and disturbances in coagulation. Yet persistent symptoms do not necessarily arise from the same mechanism in every patient. A treatment that targets angiotensin signaling may be most relevant to vascular or myocardial changes, whereas an anti-inflammatory steroid may be more useful when immune activation is prominent. Carefully characterized trials could therefore help move long-COVID care away from a single universal treatment and toward biologically defined, individualized strategies.
The citation identifies the work as a randomized, double-blind, placebo-controlled investigation of losartan and prednisolone, but the bibliographic information provided here does not include numerical results, participant outcomes or the authors’ final estimates of treatment effectiveness. Those details are essential for judging whether either drug improved symptoms, cardiac imaging findings or biomarkers, and for assessing possible adverse effects. Until the complete trial data are examined, the study should be understood as evidence from a structured clinical test of two therapeutic approaches—not as proof that either medicine is an established treatment for post-COVID syndrome. Its broader contribution lies in applying rigorous cardiovascular and immunological methods to a persistent consequence of viral disease.
Subject of Research: Post-COVID syndrome and cardiac inflammation
Article Title: Losartan and prednisolone for post-COVID syndrome and cardiac inflammation: a randomized, double-blind, placebo-controlled trial
Article References: Puntmann, V.O., Nagel, E., Beitzke, D. et al. Losartan and prednisolone for post-COVID syndrome and cardiac inflammation: a randomized, double-blind, placebo-controlled trial. Nat Commun 17, 7599 (2026). https://doi.org/10.1038/s41467-026-75991-w
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41467-026-75991-w
Keywords: Post-COVID syndrome, long COVID, cardiac inflammation, SARS-CoV-2, losartan, prednisolone, cardiovascular disease, randomized controlled trial
Tags: corticosteroids in long COVID managementCOVID-19 and cardiac inflammationeffects of losartan on post-viral cardiac damageimmune dysregulation after COVID-19long COVID cardiovascular symptomslosartan for post-COVID inflammationnon-pharmaceutical interventions for long COVIDpersistent inflammation in post-COVID patientsPost-COVID syndrome treatmentprednisolone for long COVID symptomsRandomized controlled trial COVID-19vascular damage and clotting in COVID-19
